Q32 Bio Inc.
QTTBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 28, 2026 | Jefferies | Maury Raycroft | $29.00(+231%) | $8.77 | TheFly |
| Aug 24, 2026 | Morgan Stanley | Judah Frommer | $34.00(+113%) | $15.97 | StreetInsider |
| Jul 28, 2026 | H.C. Wainwright | Joseph Pantginis | $36.00(+137%) | $15.21 | StreetInsider |
| Jul 13, 2026 | Wells Fargo | Derek Archila | $66.00(+225%) | $20.29 | TheFly |
| Jul 13, 2026 | Oppenheimer | $40.00(+93%) | $20.72 | StreetInsider | |
| May 22, 2026 | Mizuho Securities | Joseph Catanzaro | $14.00(+155%) | $5.50 | TheFly |
| Mar 10, 2026 | H.C. Wainwright | Joseph Pantginis | $13.00(+117%) | $5.99 | StreetInsider |
| Dec 5, 2024 | BMO Capital | Etzer Darout | $64.00(+170%) | $23.69 | StreetInsider |
| Oct 16, 2024 | Oppenheimer | Jay Olson | $80.00(+65%) | $48.47 | StreetInsider |
| Sep 11, 2024 | Wells Fargo | Derek Archila | $95.00(+88%) | $50.61 | StreetInsider |
| May 21, 2024 | Leerink Partners | Thomas Smith | $54.00(+79%) | $30.20 | TheFly |
| Apr 10, 2024 | Oppenheimer | Jay Olson | $50.00(+133%) | $21.48 | StreetInsider |
| Apr 2, 2024 | Raymond James | Christopher Raymond | $45.00(+150%) | $18.00 | TheFly |
| Apr 2, 2024 | Piper Sandler | Allison Bratzel | $45.00(+150%) | $18.00 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 28, 2026 |
| Oppenheimer | maintain | Outperform | Jul 13, 2026 |
| Wells Fargo | upgrade | Equal Weight →Overweight | Jul 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 5, 2026 |
| Wells Fargo | maintain | Equal Weight | Mar 12, 2025 |
| BMO Capital | downgrade | Outperform →Market Perform | Feb 11, 2025 |
| Piper Sandler | downgrade | Overweight →Neutral | Feb 11, 2025 |
| BMO Capital | maintain | Outperform | Dec 12, 2024 |
| Guggenheim | downgrade | Buy →Neutral | Dec 12, 2024 |
| Oppenheimer | maintain | Outperform | Dec 11, 2024 |
| Piper Sandler | maintain | Overweight | Dec 11, 2024 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Dec 11, 2024 |
| Leerink Partners | downgrade | Outperform →Market Perform | Dec 11, 2024 |
| Raymond James | downgrade | Strong Buy →Outperform | Dec 11, 2024 |
Earnings History
Next report: Mar 9, 2027 · EPS est. $-0.30| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-0.26 | $-0.33 | — | — |
| Aug 5, 2026 | $-0.44 | $-0.53 | — | $1.0M |
| May 5, 2026 | $-0.54 | $-0.68 | — | — |
| Mar 10, 2026 | $3.65 | $-0.85 | $53.7M | $53.7M |
| Nov 13, 2025 | $-0.60 | $-1.39 | — | — |
| Aug 6, 2025 | $-0.78 | $-1.14 | — | — |
| May 8, 2025 | $-0.90 | $-1.23 | — | — |
| Mar 11, 2025 | $-1.16 | $-1.25 | — | — |
News
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of bempikibart as a chronic treatment in AA -- -- Robust durability, including maintenance and deepening of response, observed through the 16-week off-drug period in Part B supporting potential for less frequent, chronic maintenance dosing -- -- SIGNAL-AA Part B open…
Q32 Bio (NASDAQ: QTTB - Get Free Report) and Applied Therapeutics (NASDAQ: APLT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Institutional and Insider Ownership 31.3% of Q32
-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing -- -- Mechanism of action supported by biomarker results and biopsy findings -- -- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals -- -- Data supports further deve…
Q32 Bio'S bempikibart could offer lasting hair regrowth in alopecia areata, but its potential advantage still depends on broader clinical validation. For now, QTTB's improved financing gives them room to maneuver in the short term, which helps de-risk the stock as well. That means QTTB's subsequent updates by 2H2026, 1H2027, and 2H2027 are what will ultimately make or break my bull case on the stock.
-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata -- WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-…
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory strategy -- WALTHAM, Mass., Sept. 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areat…
The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Atlas Venture Life Science Advisors LLC grew its position in Q32 Bio Inc. (NASDAQ: QTTB) by 29.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,717,106 shares of the company's stock after purchasing an additional 625,000 shares during the period. Q32 Bio makes
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026Fireside Chat Presentation Time: 3:45 p.m.
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.